Phenotypes Associated with This Genotype

Genotype
MGI:5827761

• Allelic Composition: Tg(MMTV-KRAS*G12V)3025Mrl/0; Tg(MMTV-rtTA)1Lach/0; Tg(tetO-MYC)1Lach/0
• Genetic Background: involves: C57BL/6 * FVB/N * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased mammary gland tumor incidence ( J:133578 )

• mice fed doxycycline develop tumors in all mammary glands within 10 weeks of induction, with a median latency between 6 and 8 weeks

• removal of doxycycline results in apoptosis and reduced proliferation of tumors

• after doxycycline withdrawal, tumors become smaller within 5-7 days of withdrawal, however, none of the palpable tumors regress completely after 3 weeks and begin to regrow within 3-6 weeks

integument

increased mammary gland tumor incidence ( J:133578 )

• mice fed doxycycline develop tumors in all mammary glands within 10 weeks of induction, with a median latency between 6 and 8 weeks

• removal of doxycycline results in apoptosis and reduced proliferation of tumors

• after doxycycline withdrawal, tumors become smaller within 5-7 days of withdrawal, however, none of the palpable tumors regress completely after 3 weeks and begin to regrow within 3-6 weeks

endocrine/exocrine glands

increased mammary gland tumor incidence ( J:133578 )

• mice fed doxycycline develop tumors in all mammary glands within 10 weeks of induction, with a median latency between 6 and 8 weeks

• removal of doxycycline results in apoptosis and reduced proliferation of tumors

• after doxycycline withdrawal, tumors become smaller within 5-7 days of withdrawal, however, none of the palpable tumors regress completely after 3 weeks and begin to regrow within 3-6 weeks

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
breast cancer		DOID:1612	OMIM:114480	J:133578